Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Therapies under investigation for multiple sclerosis Stories

New Drug Shows Promise Against Multiple Sclerosis
2011-11-02 04:45:28

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men. The study, carried out by researchers at UCSF Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British...

2011-10-20 01:00:00

PARIS, October 20, 2011 /PRNewswire/ -- - New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress - - U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly...

2011-10-06 10:58:34

The drug also increased the length of time before a patient relapsed and more patients taking it remained free of relapses A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the drug teriflunomide were published in The New England Journal of Medicine on Thursday. "This could be a safe, effective and convenient...

2011-10-05 16:29:00

PARIS, Oct. 5, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM). Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity,...

2011-06-21 12:30:17

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) "” a chronic inflammatory disease of the central nervous system. Dr Bruno Gran, a Clinical Associate Professor in the Division of Clinical Neurology in the School of Clinical Sciences, working in collaboration with Professor Paul Moynagh from the National University of Ireland, Maynooth, has discovered a synthetic chemical...

2011-04-11 00:30:00

EAST HANOVER, N.J., April 11, 2011 /PRNewswire/ -- A new analysis demonstrated that Gilenya(TM) (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology (AAN). "In developing Gilenya, Novartis initiated a large clinical trial...

2011-02-10 16:10:00

EMERYVILLE, Calif., Feb. 10, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today articulated for investors the Company's plan of action for 2011 in the development of MF101 (Menerba(TM)). The company also updated its investor information, available on the company's website. "Having positive clinical and non-clinical data to date, regulatory clarity on...

2010-11-02 08:13:00

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs). In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications,...

2010-10-26 00:00:00

PARIS, October 26, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical...

2010-10-15 02:15:00

PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate...